Literature DB >> 16773572

Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype.

Claudio Carta1, Francesca Pantaleoni, Gianfranco Bocchinfuso, Lorenzo Stella, Isabella Vasta, Anna Sarkozy, Cristina Digilio, Antonio Palleschi, Antonio Pizzuti, Paola Grammatico, Giuseppe Zampino, Bruno Dallapiccola, Bruce D Gelb, Marco Tartaglia.   

Abstract

Noonan syndrome (NS) is a developmental disorder characterized by short stature, facial dysmorphia, congenital heart disease, and multiple skeletal and hematologic defects. NS is an autosomal dominant trait and is genetically heterogeneous. Gain of function of SHP-2, a protein tyrosine phosphatase that positively modulates RAS signaling, is observed in nearly 50% of affected individuals. Here, we report the identification of heterozygous KRAS gene mutations in two subjects exhibiting a severe NS phenotype with features overlapping those of cardiofaciocutaneous and Costello syndromes. Both mutations were de novo and affected exon 6, which encodes the C-terminal portion of KRAS isoform B but does not contribute to KRAS isoform A. Structural analysis indicated that both substitutions (Val152Gly and Asp153Val) perturb the conformation of the guanine ring-binding pocket of the protein, predicting an increase in the guanine diphosphate/guanine triphosphate (GTP) dissociation rate that would favor GTP binding to the KRASB isoform and bypass the requirement for a guanine nucleotide exchange factor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773572      PMCID: PMC1474118          DOI: 10.1086/504394

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  54 in total

1.  Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS.

Authors:  S Mariana Margarit; Holger Sondermann; Brian E Hall; Bhushan Nagar; Andre Hoelz; Michelle Pirruccello; Dafna Bar-Sagi; John Kuriyan
Journal:  Cell       Date:  2003-03-07       Impact factor: 41.582

Review 2.  Ras-effector interactions: after one decade.

Authors:  Christian Herrmann
Journal:  Curr Opin Struct Biol       Date:  2003-02       Impact factor: 6.809

Review 3.  Mechanisms of Ras protein targeting in mammalian cells.

Authors:  J R Silvius
Journal:  J Membr Biol       Date:  2002-11-15       Impact factor: 1.843

4.  Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal.

Authors:  B Marino; M C Digilio; A Toscano; A Giannotti; B Dallapiccola
Journal:  J Pediatr       Date:  1999-12       Impact factor: 4.406

5.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.

Authors:  Marco Tartaglia; Kamini Kalidas; Adam Shaw; Xiaoling Song; Dan L Musat; Ineke van der Burgt; Han G Brunner; Débora R Bertola; Andrew Crosby; Andra Ion; Raju S Kucherlapati; Steve Jeffery; Michael A Patton; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2002-05-01       Impact factor: 11.025

Review 6.  Blocking oncogenic Ras signaling for cancer therapy.

Authors:  A A Adjei
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

7.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.

Authors:  M Tartaglia; E L Mehler; R Goldberg; G Zampino; H G Brunner; H Kremer; I van der Burgt; A H Crosby; A Ion; S Jeffery; K Kalidas; M A Patton; R S Kucherlapati; B D Gelb
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

Review 8.  CFC index for the diagnosis of cardiofaciocutaneous syndrome.

Authors:  M I Kavamura; C A Peres; M M A Alchorne; D Brunoni
Journal:  Am J Med Genet       Date:  2002-09-15

9.  PTPN11 mutations in LEOPARD syndrome.

Authors:  E Legius; C Schrander-Stumpel; E Schollen; C Pulles-Heintzberger; M Gewillig; J-P Fryns
Journal:  J Med Genet       Date:  2002-08       Impact factor: 6.318

10.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.

Authors:  Maria Cristina Digilio; Emanuela Conti; Anna Sarkozy; Rita Mingarelli; Tania Dottorini; Bruno Marino; Antonio Pizzuti; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

View more
  76 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

Review 2.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

3.  Role of genomics in cardiovascular medicine.

Authors:  Giuseppe Novelli; Irene M Predazzi; Ruggiero Mango; Francesco Romeo; Jawahar L Mehta
Journal:  World J Cardiol       Date:  2010-12-26

4.  Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors.

Authors:  Ramin Ekhteiari Salmas; Mert Mestanoglu; Mine Yurtsever; Sergei Y Noskov; Serdar Durdagi
Journal:  Biophys J       Date:  2015-09-01       Impact factor: 4.033

5.  Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.

Authors:  Masako Yaoita; Tetsuya Niihori; Seiji Mizuno; Nobuhiko Okamoto; Shion Hayashi; Atsushi Watanabe; Masato Yokozawa; Hiroshi Suzumura; Akihiko Nakahara; Yusuke Nakano; Tatsunori Hokosaki; Ayumi Ohmori; Hirofumi Sawada; Ohsuke Migita; Aya Mima; Pablo Lapunzina; Fernando Santos-Simarro; Sixto García-Miñaúr; Tsutomu Ogata; Hiroshi Kawame; Kenji Kurosawa; Hirofumi Ohashi; Shin-Ichi Inoue; Yoichi Matsubara; Shigeo Kure; Yoko Aoki
Journal:  Hum Genet       Date:  2015-12-29       Impact factor: 4.132

6.  Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.

Authors:  Yline Capri; Elisabetta Flex; Oliver H F Krumbach; Giovanna Carpentieri; Serena Cecchetti; Christina Lißewski; Soheila Rezaei Adariani; Denny Schanze; Julia Brinkmann; Juliette Piard; Francesca Pantaleoni; Francesca R Lepri; Elaine Suk-Ying Goh; Karen Chong; Elliot Stieglitz; Julia Meyer; Alma Kuechler; Nuria C Bramswig; Stephanie Sacharow; Marion Strullu; Yoann Vial; Cédric Vignal; George Kensah; Goran Cuturilo; Neda S Kazemein Jasemi; Radovan Dvorsky; Kristin G Monaghan; Lisa M Vincent; Hélène Cavé; Alain Verloes; Mohammad R Ahmadian; Marco Tartaglia; Martin Zenker
Journal:  Am J Hum Genet       Date:  2019-05-23       Impact factor: 11.025

Review 7.  Mitogen-activated protein kinases in heart development and diseases.

Authors:  Yibin Wang
Journal:  Circulation       Date:  2007-09-18       Impact factor: 29.690

8.  Biochemical and functional characterization of germ line KRAS mutations.

Authors:  Suzanne Schubbert; Gideon Bollag; Natalya Lyubynska; Hoa Nguyen; Christian P Kratz; Martin Zenker; Charlotte M Niemeyer; Anders Molven; Kevin Shannon
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

Review 9.  Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature.

Authors:  Fu-Sung Lo; Ju-Li Lin; Min-Tzu Kuo; Pao-Chin Chiu; San-Ging Shu; Mei-Chyn Chao; Yann-Jinn Lee; Shuan-Pei Lin
Journal:  Eur J Pediatr       Date:  2008-10-29       Impact factor: 3.183

10.  Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.

Authors:  Zhi-Hong Yu; Jie Xu; Chad D Walls; Lan Chen; Sheng Zhang; Ruoyu Zhang; Li Wu; Lina Wang; Sijiu Liu; Zhong-Yin Zhang
Journal:  J Biol Chem       Date:  2013-03-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.